Find enclosed the press release on the audited financial results for the year ended March 31,2025
Awaiting price reaction for this filing.
P&G Hygiene and Health Care announced its FY25 results, covering a 9-month transitional period from July 1, 2024 to March 31, 2025, as the company shifted its financial year from a July–June cycle to align with April–March. For this 9-month period, sales stood at ₹3,374 crore, up 3% versus the comparable prior-year period, while Profit After Tax rose 7% to ₹636 crore. Standalone Q3 sales were flat year-on-year at ₹992 crore, with Q3 PAT at ₹156 crore. The Board has recommended a final dividend of ₹65 per share, taking total dividend for the fiscal to ₹175 per share (including the interim ₹110), pending shareholder approval at the 61st AGM.
Modest top-line growth and stronger profit growth reflect resilient demand despite a tough macro environment, while a healthy total dividend of ₹175 per share is a positive for shareholders. The shift to an April–March financial year means FY26 numbers will be the first directly comparable to a full prior year.